Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
NRG Oncology
NRG Oncology
UNC Lineberger Comprehensive Cancer Center
Genmab
Fulgent Pharma LLC.
Hoffmann-La Roche
Eastern Cooperative Oncology Group
University of Chicago
University of Chicago
Neonc Technologies, Inc.
Gilead Sciences
NRG Oncology
Ohio State University Comprehensive Cancer Center
National Medical Research Radiological Centre of the Ministry of Health of Russia
University of Chicago
Wake Forest University Health Sciences
University of Michigan Rogel Cancer Center
M.D. Anderson Cancer Center
University of Chicago
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Fate Therapeutics
Merck Sharp & Dohme LLC
Adlai Nortye Biopharma Co., Ltd.
Rakuten Medical, Inc.
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Hoffmann-La Roche
Nurix Therapeutics, Inc.
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Merck Sharp & Dohme LLC
University of Michigan Rogel Cancer Center
Dana-Farber Cancer Institute
Memorial Sloan Kettering Cancer Center
invoX Pharma Limited
Iovance Biotherapeutics, Inc.
Merck Sharp & Dohme LLC
University of Chicago
DEKA Biosciences
University of Michigan Rogel Cancer Center
University of Chicago
Medical University of Vienna
University of Chicago
Thomas Jefferson University
Replimune Inc.
Fudan University
Ohio State University Comprehensive Cancer Center
Latin American Cooperative Oncology Group
AstraZeneca
Suzhou Junde Biotechnology Co., Ltd